Treatment Duration in Patients With Transplant-Ineligible NDMM

Video

Shared perspectives on the role of continued therapy in patients with transplant-ineligible newly diagnosed multiple myeloma in light of clinical data and dose adjustment strategies.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
In the UK, the Medicines and Healthcare products Regulatory Agency approved the belantamab mafodotin combinations in April 2025 based on findings from the DREAMM-7 and DREAMM-8 trials.

Belantamab Mafodotin Earns Japanese Approval in R/R Multiple Myeloma

Russ Conroy
May 19th 2025
Article

Data from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin for patients with relapsed/refractory multiple myeloma in Japan.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

The safety profile of daratumumab plus bortezomib, melphalan, and prednisone remained stable at follow-up, and no new safety signals were observed.

Daratumumab Combo Prolonged Efficacy in Asian Patients with Multiple Myeloma

Roman Fabbricatore
May 17th 2025
Article

The safety profile of daratumumab plus bortezomib, melphalan, and prednisone remained stable at follow-up, and no new safety signals were observed.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Developers designed cemsidomide as an orally bioavailable small molecule degrader that targets IKZF1/3, which drive multiple myeloma and non-Hodgkin lymphoma.

Cemsidomide Combo May Produce Responses in Multiple Myeloma

Russ Conroy
May 8th 2025
Article

Investigators of the phase 1/2 CFT7455-1101 study have determined cemsidomide at a dose of 100 µg safe for expansion.

Developers designed ISB 2001 to target BCMA and CD38 expressed on myeloma cells as well as CD3 on T cells.

FDA Gives Fast-Track Designation to ISB 2001 in Relapsed/Refractory Myeloma

Russ Conroy
May 7th 2025
Article

Phase 1 data demonstrate enduring responses with ISB 2001 among patients with relapsed/refractory multiple myeloma.